Coley, H. M., Safuwan, N. A. M., Chivers, P., Papacharalbous, E., Giannopoulos, T., Butler-Manuel, S., . . . Crook, T. (2012). The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. Nature Publishing Group.

Coley, H M., N A M. Safuwan, P. Chivers, E. Papacharalbous, T. Giannopoulos, S. Butler-Manuel, K. Madhuri, D P. Lovell, and T. Crook. The Cyclin-dependent Kinase Inhibitor P57(Kip2) Is Epigenetically Regulated in Carboplatin Resistance and Results in Collateral Sensitivity to the CDK Inhibitor Seliciclib in Ovarian Cancer. Nature Publishing Group, 2012.

Coley, H M., et al. The Cyclin-dependent Kinase Inhibitor P57(Kip2) Is Epigenetically Regulated in Carboplatin Resistance and Results in Collateral Sensitivity to the CDK Inhibitor Seliciclib in Ovarian Cancer. Nature Publishing Group, 2012.